Search Results

You are looking at 1 - 10 of 51 items for :

  • "papillary thyroid carcinoma" x
Clear All
Open access

June Young Choi, Jin Wook Yi, Jun Hyup Lee, Ra-Yeong Song, Hyeongwon Yu, Hyungju Kwon, Young Jun Chai, Su-jin Kim and Kyu Eun Lee

( s.e.m. )). Figure 1 VDR mRNA expression counts in normal and papillary thyroid carcinoma tissue. (A) Fifty-nine paired normal and cancer tissues. (B) 59 normal vs 501 cancer tissues. Correlations of VDR mRNA expression according

Open access

Wei Li, Qing Huang, Danyang Sun, Guizhi Zhang and Jian Tan

Introduction Papillary thyroid carcinoma (PTC) is the most common subtype of thyroid cancer. In 2008, the incidence of thyroid cancer was 1.4/100,000, and it accounts for 0.8% of all malignancies in China (0.4% of those in men, 1.3% in women

Open access

Huy Gia Vuong, Nguyen Phuoc Long, Nguyen Hoang Anh, Tran Diem Nghi, Mai Van Hieu, Le Phi Hung, Tadao Nakazawa, Ryohei Katoh and Tetsuo Kondo

, undifferentiated and medullary carcinoma ( 2 ). Papillary thyroid carcinoma (PTC) is the most common subtype, which comprises more than 85% of thyroid cancers. Morphologically, PTCs are subdivided into variants, of which tall cell variant (TCV) is recognized as

Open access

Lauren E Henke, John D Pfeifer, Thomas J Baranski, Todd DeWees and Perry W Grigsby

Introduction Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy, accounting for 88% of thyroid carcinomas ( 1 , 2 ). Prognosis remains excellent and treatment, typically involving surgery followed by radioactive iodine

Open access

Huy Gia Vuong, Uyen N P Duong, Ahmed M A Altibi, Hanh T T Ngo, Thong Quang Pham, Hung Minh Tran, Greta Gandolfi and Lewis Hassell

– 50 . ( doi:10.1200/JCO.2014.56.8253 ) 6 Ito Y Yoshida H Kihara M Kobayashi K Miya A Miyauchi A. BRAFV600E mutation analysis in papillary thyroid carcinoma: Is it useful for all patients? World Journal of Surgery 2014

Open access

Changjiao Yan, Meiling Huang, Xin Li, Ting Wang and Rui Ling

, the disease stage of three patients cannot be determined. In patients with BRAF V600E mutations, the disease stage of 73 patients cannot be determined. CPTC, conventional papillary thyroid carcinoma; FVPTC, follicular variant papillary thyroid

Open access

Ana Carolina de Jesus Paniza, Thais Biude Mendes, Matheus Duarte Borges Viana, Débora Mota Dias Thomaz, Paula B O Chiappini, Gabriel A Colozza-Gama, Susan Chow Lindsey, Marcos Brasilino de Carvalho, Venâncio Avancini Ferreira Alves, Otavio Curioni, André Uchimura Bastos and Janete Maria Cerutti

thyroid carcinoma (PTC), the increase can also be partially ascribed to the evolution of histological criteria for the diagnosis of follicular variant of papillary thyroid carcinoma (FVPTC) ( 1 , 2 , 3 , 4 , 5 , 6 ). This variant is composed

Open access

Marco Marino, Valentina Cirello, Valentina Gnarini, Carla Colombo, Elisa Pignatti, Livio Casarini, Chiara Diazzi, Vincenzo Rochira, Katia Cioni, Bruno Madeo, Cesare Carani, Manuela Simoni and Laura Fugazzola

Introduction Thyroid cancers can be well-differentiated, as papillary and follicular subtypes, or poorly differentiated and anaplastic carcinomas. Papillary thyroid carcinoma (PTC) represents up to 80% of all the thyroid cancer cases. Various

Open access

Guoquan Zhu, Yuying Deng, Liqin Pan, Wei Ouyang, Huijuan Feng, Juqing Wu, Pan Chen, Jing Wang, Yanying Chen and Jiaxin Luo

the completion of initial surgical treatment. PTC, papillary thyroid carcinoma; s.d. , standard deviation. Clinical and pathologic differences in PTCs with the BRAF V600E mutation Of the 1220 patients who were included in

Open access

Klaudia Zajkowska, Janusz Kopczyński, Stanisław Góźdź and Aldona Kowalska

Introduction The follicular variant of papillary thyroid carcinoma (FVPTC) is the second most common histological variant of papillary thyroid carcinoma (PTC) ( 1 ). There are two variants of FVPTC, non-encapsulated (infiltrative) and